The long-standing, successful use of radio-theranostics in imaging and therapy is based on targeting radiolabeled molecules to tumors or other diseased tissues. Over 10,000 hospitals worldwide use radioisotopes for in-vivo diagnosis or treatment, reaching around 35 million patients each year. The ideal cancer imaging tool is a homogenous conjugate with a precisely defined payload-to-carrier ratio, showing specific tumor-targeting with minimal side-effects and fast clearance.
Navigo’s Affilin® radio conjugates are homogenous, site-specific conjugates of Affilin® ligands with isotope-loaded chelators and thus therapeutic product candidates with defined isotope-to-carrier ratios. Chelators can be loaded with different radioactive isotopes for imaging or therapy purposes. On top of that, specific half-life can be readily adjusted, to balance optimal tumor uptake with circulation residence time, for maximized imaging contrast and minimal side effects. Thus, Affilin®-radio conjugates promise significantly improved therapeutic and diagnostic performance.
Classical Antibody Radio Conjugates are complex to develop and produce suffer from several disadvantages, such as non-specific conjugation, heterogeneous isotope-to-antibody ratios, plus long residence times in the circulation and non-tumorigenic tissues. Navigo’s Affilin®-radio conjugates in contrast have the potential to become next-generation radio therapeutics.
Theranostics: The modularity and ease of construction of Affilin®-based therapeutics could have a great potential in theranostic applications, for e.g., sequential purposes of imaging, radiotherapy, and radiotherapy-monitoring.
Affilin® radio conjugates with homogenous isotope-to-carrier ratios can be easily assembled by engineering target-binding Affilin® molecules together with isotope-loaded chelators. To attune Affilin® radio conjugates for therapeutic or imaging purposes, both the loaded radionuclide as well as the specific half-life of the conjugate can be optimized.